Maximum value will be achieved once the Phase 3 trials are complete.
Combining information for the Investor Webinar and the numbers provided by Little T above you can see that NEU are in a very strong financial position and can afford to fund two Phase 3 trials.
Jon Pilcher says the cost of running a Phase 3 trail could be between US$50m and US$150m (A$75m to A$225m).
The numbers above from Little T indicate there is sufficient funds:
+ $213m cash on hand (30th June 2024)
+ $10m interest potential (c.5%) on cash balance
+ $50m (US$33m) 1/3 of Priority Review Voucher
+ $150m (US$100m) full value of Priority Review Voucher for NNZ259
+ Ongoing royalties Daybue royalties
= more than enough cash to run two Phase 3 trials
From a timing perspective it could take 2-3 years (based on Trof P3 + FDA approval) but assuming they are successful would result in a significant increase in value for NEU and all shareholders.
Here's the link to the webinar so people can hear it direct from Jon. It's a worthwhile investment of time for any Investor in NEU:
Neuren Investor Webinar - NNZ-2591 Angelman syndrome Phase 2 trial top-line results
- Forums
- ASX - By Stock
- NEU
- NEU is materially undervalued
NEU is materially undervalued, page-11
-
- There are more pages in this discussion • 49 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$13.76 |
Change
0.150(1.10%) |
Mkt cap ! $1.758B |
Open | High | Low | Value | Volume |
$13.60 | $14.00 | $13.51 | $5.043M | 365.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 3816 | $13.73 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.78 | 2834 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | 13.620 |
2 | 733 | 13.510 |
7 | 9120 | 13.500 |
1 | 1000 | 13.480 |
1 | 50 | 13.420 |
Price($) | Vol. | No. |
---|---|---|
13.960 | 2652 | 1 |
14.000 | 6595 | 2 |
14.110 | 1000 | 1 |
14.120 | 493 | 1 |
14.250 | 1000 | 1 |
Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online